An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery

DMM Disease Models and Mechanisms

Volumn 6, Issue 2, 2013, Pages 521-529

  Willoughby, Lee F ^a   Schlosser, Tanja ^a   Manning, Samuel A ^a   Parisot, John P ^a,b,c   Street, Ian P ^b,c   Richardson, Helena E ^a   Humbert, Patrick O ^a   Brumby, Anthony M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ACIVICIN; AMINOOXYACETIC ACID; ANTINEOPLASTIC AGENT; CYTIDINE TRIPHOSPHATE SYNTHASE; GLUTAMINE DERIVATIVE; IDARUBICIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DROSOPHILA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; IN VIVO STUDY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; CYTIDINE TRIPHOSPHATE; DIPHENYLAMINE; DROSOPHILA MELANOGASTER; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTAMINE; ISOXAZOLES; NEOPLASMS; PHARMACOGENETICS; PILOT PROJECTS;

EID: 84875130582     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.009985     Document Type: Article

References (36)

1. Agrawal, N., Pallos, J., Slepko, N., Apostol, B. L., Bodai, L., Chang, L. W., Chiang, A. S., Thompson, L. M. and Marsh, J. L. (2005). Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. USA 102, 3777-3781. (Pubitemid 40354688)
2. Ahluwalia, G. S., Grem, J. L., Hao, Z. and Cooney, D. A. (1990). Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 46, 243-271. (Pubitemid 20094962)
3. Aritakula, A. and Ramasamy, A. (2008). Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway. J. Biosci. 33, 731-742.
4. Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., Le Page, S., Leopold, W. R. et al. (2008). The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 18, 6501-6504.
5. Brumby, A. M. and Richardson, H. E. (2003). scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila. EMBO J. 22, 5769-5779. (Pubitemid 37408816)
6. Brumby, A. M. and Richardson, H. E. (2005). Using Drosophila melanogaster to map human cancer pathways. Nat. Rev. Cancer 5, 626-639. (Pubitemid 41081388)
7. Chang, S., Bray, S. M., Li, Z., Zarnescu, D. C., He, C., Jin, P. and Warren, S. T. (2008). Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256-263. (Pubitemid 351419125)
8. Chen, K., Zhang, J., Tastan, O. Y., Deussen, Z. A., Siswick, M. Y. and Liu, J. L. (2011). Glutamine analogs promote cytoophidium assembly in human and Drosophila cells. J. Genet. Genomics 38, 391-402.
9. Colombani, J., Andersen, D. S. and Leopold, P. (2012). Secreted peptide Dilp8 coordinates Drosophila tissue growth with developmental timing. Science 336, 582-585.
10. Cordero, J. B., Macagno, J. P., Stefanatos, R. K., Strathdee, K. E., Cagan, R. L. and Vidal, M. (2010). Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev. Cell 18, 999-1011.
11. Dar, A. C., Das, T. K., Shokat, K. M. and Cagan, R. L. (2012). Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80-84.
12. De Berardinis, R. J. and Cheng, T. (2010). Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324.
13. Denton, J. E., Lui, M. S., Aoki, T., Sebolt, J. and Weber, G. (1982). Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatoma. Life Sci. 30, 1073-1080. (Pubitemid 12100133)
14. Earhart, R. H. and Neil, G. L. (1985). Acivicin in 1985. Adv. Enzyme Regul. 24, 179-205.
15. Edwards, A., Gladstone, M., Yoon, P., Raben, D., Frederick, B. and Su, T. T. (2011). Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis. Model. Mech. 4, 496-503.
16. Ellims, P. H., Gan, T. E. and Medley, G. (1983). Cytidine triphosphate synthetase activity in lymphoproliferative disorders. Cancer Res. 43, 1432-1435. (Pubitemid 13160081)
17. Garelli, A., Gontijo, A. M., Miguela, V., Caparros, E. and Dominguez, M. (2012). Imaginal discs secrete insulin-like peptide 8 to mediate plasticity of growth and maturation. Science 336, 579-582.
18. Gladstone, M. and Su, T. T. (2011). Chemical genetics and drug screening in Drosophila cancer models. J. Genet. Genomics 38, 497-504.
19. Goebel, M. (1993). Oral idarubicin - an anthracycline derivative with unique properties. Ann. Hematol. 66, 33-43. (Pubitemid 23066935)
20. Jayaram, H. N., Cooney, D. A., Ryan, J. A., Neil, G., Dion, R. L. and Bono, V. H. (1975). L-[alphaS, 5S]-alpha-amino-3-chloro-4, 5-dihydro-5- isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother. Rep. 59, 481-491.
21. Kang, H. L, Benzer, S. and Min, K. T. (2002). Life extension in Drosophila by feeding a drug. Proc. Natl. Acad. Sci. USA 99, 838-843. (Pubitemid 34106597)
22. Kizaki, H., Williams, J. C, Morris, H. P. and Weber, G. (1980). Increased cytidine 5-triphosphate synthetase activity in rat and human tumors. Cancer Res. 40, 3921-3927. (Pubitemid 10030406)
23. McBride, S. M., Choi, C. H., Wang, Y., Liebelt, D., Braunstein, E., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C, Nguyen, H. T. et al. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45, 753-764. (Pubitemid 40320709)
24. McPartland, R. P., Wang, M. C, Bloch, A. and Weinfeld, H. (1974). Cytidine 5-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine. Cancer Res. 34, 3107-3111.
25. Moreadith, R. W. and Lehninger, A. L. (1984). The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD (P) +- dependent malic enzyme. J. Biol Chem. 259, 6215-6221. (Pubitemid 14106333)
26. Pagliarini, R. A. and Xu, T. (2003). A genetic screen in Drosophila for metastatic behavior. Science 302, 1227-1231. (Pubitemid 37421030)
27. Pandey, U. B. and Nichols, C. D. (2011). Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 63, 411-436.
28. Pastor-Pareja, J. C., Wu, M. and Xu, T. (2008). An innate immune response of blood cells to tumors and tissue damage in Drosophila. Dis. Model. Mech. 1, 144-154.
29. Shah, S., Yarrow, C., Dunning, R., Cheek, B., Vass, S., Windass, J. and Hadfield, S. (2012). Insecticide detoxification indicator strains as tools for enhancing chemical discovery screens. Pest Manag. Sci. 68, 38-48.
30. Stilwell, G. E., Saraswati, S., Littleton, J. T. and Chouinard, S. W. (2006). Development of a Drosophila seizure model for in vivo high-throughput drug screening. Eur. J. Neurosci. 24, 2211-2222. (Pubitemid 44622342)
31. Ursprung, H. (1967). In vivo culture of Drosophila imaginal discs. In Methods in Developmental Biology (ed. F. H. Wilt and N. K. Wessells), pp. 485-492. New York, NY: Thomas Y. Cromwell Company.
32. Vidal, M., Wells, S., Ryan, A. and Cagan, R. (2005). ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65, 3538-3541. (Pubitemid 40616327)
33. Willecke, M., Toggweiler, J. and Basler, K. (2011). Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model. Oncogene 30, 4067-4074.
34. Williams, J. C., Kizaki, H., Weber, G. and Morris, H. P. (1978). Increased CTP synthetase activity in cancer cells. Nature 271, 71-73. (Pubitemid 8240069)
35. Wise, D. R. and Thompson, C. B. (2010). Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427-433.
36. Zhang, J. H., Chung, T. D. and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73. (Pubitemid 29278954)